GLP-1medications are being explored as a potentialtreatmentforbingeeatingdisorder — not just for weight loss, but for how they affect reward pathways in the brain. Here's what the early research shows and what patients should know.
Overall, clarification of the role ofGLP-1signaling inbingeeatingand the potential utility of targetingGLP-1Rs to reduce motivation and craving for palatable foods and to improve satiety, could be of great utility in thinking about strategies to reducebingeeatingand potentially could improvetreatmentofeatingdisorders with a ...
Furthermore, visual representations like the one above help us fully grasp the concept of Binge Eating Treatment With Glp-1.
In summary, whileGLP-1medications have been found to be helpful in thetreatmentof Type 2 diabetes and reduction of cardiovascular mortality, for individuals witheatingdisorders or disorderedeatingbehaviors, these drugs can be harmful when not used for their intended purpose, when inadequately monitored or monitored by clinicians withouteatingdisorder expertise, or when used for ...
Agonist use in patients witheatingdisorders should be approached cautiously. A recent systematic review and meta-analysis (Eat Weight Disord. 2025; 30:10) explored the potential of glucagon-like peptide-1 (GLP-1) receptor agonists in treatingeatingdisorders, particularlybingeeatingdisorder (BED).GLP-1is a natural gut hormone released aftereating. It is an anorexigenic hormone ...
Furthermore, visual representations like the one above help us fully grasp the concept of Binge Eating Treatment With Glp-1.
In a systematic review published in Pharmacotherapy, investigators evaluated the evidence for incretin‑based therapies—specificallyGLP‑1receptor agonists and dual GLP‑1/GIP agonists—for thetreatmentofbingeeating. Following PRISMA guidelines, the authors screened 1,125 records, with 12 studies meeting inclusion criteria.
